Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innate Pharma SA ( (FR:IPH) ) has provided an update.
On May 12, 2026, Innate Pharma reported its share capital and voting rights position as of April 16, 2026, in line with French market disclosure rules. The company said it had 93,934,210 shares outstanding, including ordinary and preferred stock, with 93,921,863 theoretical voting rights and 93,903,288 exercisable voting rights, providing investors with updated transparency on its capital structure.
The disclosure distinguishes between gross and net voting rights by excluding treasury shares with suspended voting rights, which are relevant for monitoring threshold crossings under French securities law. By publishing these figures for its dual listings on Euronext Paris and Nasdaq, Innate Pharma supports regulatory compliance and gives shareholders and potential investors a clearer view of its governance and ownership framework.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The French group leverages antibody engineering and innovative target identification to build a portfolio of next-generation antibody therapeutics, including candidates such as IPH4502, lacutamab and monalizumab, and maintains strategic collaborations with partners like AstraZeneca and Sanofi.
Average Trading Volume: 281,978
Technical Sentiment Signal: Sell
Current Market Cap: €117.8M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.